After OMB clarifying memo suggests freeze applies to user fee-supported staff, it could be up to FDA and stakeholders to convince the administration to spare the agency.
FDA stakeholders now may be forced to lobby for language in the White House's long-terms plans for shrinking the federal workforce to save the agency from the mandated hiring freeze.
President Trump stopped all federal hiring, except for military personnel, in a Jan. 23 executive order. He said no new...
Recent studies show that spaceflight can significantly weaken astronauts’ immune systems, making them more susceptible to infections and health complications during and after missions. Understanding these changes is crucial for ensuring the safety of future long-duration space travelers.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
Recent ODAC meetings suggest the FDA will expand focus beyond applications with pending approval decisions to refining trial designs and drug labels for competitors.
The US FDA Commissioner pushed for a rebalancing of the US’s pharmaceutical supply chains while also stressing that there is a role for US-China commerce that would be risky to compromise.
